Skip to search boxSkip to navigationSkip to main content

Association between double mutation in gyrA gene of ciprofloxacin- resistant clinical isolates of Escherichia coli and MICs

  • J. Vila(corresponding author)
    ,
  • ,
  • F. Marco
    ,
  • A. Barcelo
    ,
  • P. Goni
    ,
  • E. Giralt
*Corresponding author for this work
Research Output:
Contribution to journal
Comment/debate

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Comment/debate

Original language

English

Pages from-to (Number of pages)

Pages 2477-2479 (3 pages)

Journal (Volume, Issue Number)

Antimicrobial Agents and Chemotherapy (Volume 38, Issue 10)

Publication milestones

  • Published - 1994

Publication status

Published - 1994

ISSN

0066-4804

Publication IDs

  • Scopus: 0028144813
  • PubMed: 7840592

Abstract

The mutations in the quinolone resistance-determining region of the gyrA and gyrB genes from 27 clinical isolates of Escherichia coli with a range of MICs of ciprofloxacin from 0.007 to 128 μg/ml and of nalidixic acid from 2 to >2,000 μg/ml were determined by DNA sequencing. All 15 isolates with ciprofloxacin MICs of ≥1 μg/ml showed a change in Ser-83 to Leu of GyrA protein, whereas in clinical isolates with a MIC of ≥8 μg/ml (11 strains), a double change in Ser-83 and Asp-87 was found. All isolates with a MIC of nalidixic acid of ≥128 μg/ml showed a mutation at amino acid codon Ser-83. Only 1 of the 27 clinical isolates of E. coli analyzed showed a change in Lys-447 of the B subunit of DNA gyrase. A change in Ser-83 is sufficient to generate a high level of resistance to nalidixic acid, whereas a second mutation at Asp-87 in the A subunit of DNA gyrase may play a complementary role in developing the strain's high levels of ciprofloxacin resistance.

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Captures
116
Social media
8
Mentions
1
Citations
203

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well